Semaglutide: difference between revisions
Diff·revision 25 → 26·19:30, 4 Jul 2025
Difference between revision 25 and revision 26 of Semaglutide. 10 lines changed; the page grew by 1,239 bytes.
| Revision 25 — 05:03, 17 Jun 2025 IcodecIndra (talk) correct the molar mass — source gives the free-base figure, we had the salt 8,560 bytes ±0 | Revision 26 — 19:30, 4 Jul 2025 GroupBuyGalen (talk) state the substitution in one-letter code as well, per PP:MOS 9,799 bytes +1,239 | ||
|---|---|---|---|
| 65 | Delayed gastric emptying has prompted revised preoperative fasting guidance; see [[Aspiration risk under anaesthesia]]. A fuller account of class-wide effects is at [[Adverse effects of GLP-1 receptor agonists]]. | 65 | Delayed gastric emptying has prompted revised preoperative fasting guidance; see [[Aspiration risk under anaesthesia]]. A fuller account of class-wide effects is at [[Adverse effects of GLP-1 receptor agonists]]. |
| 66 | 66 | ||
| + | 67 | == Material sold outside licensed supply == | |
| + | 68 | Semaglutide is offered by a large number of research-chemical suppliers, generally as a lyophilised powder in 2 mg, 5 mg or 10 mg nominal fills. Such material is not the approved medicine and this wiki does not represent it as suitable for human use. | |
| + | 69 | ||
| + | 70 | Documentation quality varies widely. A [[Certificate of analysis|certificate]] reporting only an [[Area percent purity|area percent]] figure does not establish how much semaglutide a vial contains: without a [[Peptide content|peptide content]] determination and a water figure by [[Karl Fischer titration|Karl Fischer titration]], the mass of active substance cannot be calculated, and a nominal 5 mg vial may contain considerably less.{{r|usp1503}} [[Underfilling|Underfilling]] is documented in independently tested material. | |
| + | 71 | ||
| 67 | == References == | 72 | == References == |
| 68 | {{reflist}} | 73 | {{reflist}} |
| ⋮ | ⋮ | ||
| 71 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> | 76 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> |
| 72 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | 77 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> |
| + | 78 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 73 | 79 | ||
| 74 | == Further reading == | 80 | == Further reading == |
| 75 | * Mahapatra MK, Karuppasamy M, Sahoo BM. "Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits." ''Reviews in Endocrine and Metabolic Disorders'' 23(3):521–539 (2022). | 81 | * Mahapatra MK, Karuppasamy M, Sahoo BM. "Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits." ''Reviews in Endocrine and Metabolic Disorders'' 23(3):521–539 (2022). |
| + | 82 | ||
| + | 83 | == External links == | |
| + | 84 | * [https://clinicaltrials.gov/study/NCT03548935 STEP 1 — NCT03548935] — Registry record for the pivotal obesity trial. | |
| + | 85 | * [https://clinicaltrials.gov/study/NCT03574597 SELECT — NCT03574597] — Registry record for the cardiovascular outcome trial. | |
| 76 | 86 | ||
| 77 | == See also == | 87 | == See also == |